Patterns of Evidence-Based Care for the Diagnosis, Staging, and First-line Treatment of Breast Cancer by Race-Ethnicity: A SEER-Medicare Study

被引:2
|
作者
Herbach, Emma L. [1 ,2 ,6 ]
Nash, Sarah H. [1 ]
Lizarraga, Ingrid M. [3 ]
Carnahan, Ryan M. [1 ]
Wang, Kai [4 ]
Ogilvie, Amy C. [1 ]
Curran, Michaela [5 ]
Charlton, Mary E. [1 ]
机构
[1] Univ Iowa, Coll Publ Hlth, Dept Epidemiol, Iowa City, IA USA
[2] Univ Miami, Sylvester Comprehens Canc Ctr, Miller Sch Med, Miami, FL USA
[3] Univ Iowa, Carver Coll Med, Dept Surg, Iowa City, IA USA
[4] Univ Iowa, Coll Publ Hlth, Dept Biostat, Iowa City, IA USA
[5] Univ Iowa, Coll Publ Hlth, Dept Community & Behav Hlth, Iowa City, IA USA
[6] 145 N Riverside Dr CPHB, Iowa City, IA 52242 USA
关键词
RACIAL DISPARITIES; OLDER WOMEN; SURVIVAL; RACE/ETHNICITY; AMERICAN; OUTCOMES; THERAPY; TUMOR; SURVEILLANCE; QUALITY;
D O I
10.1158/1055-9965.EPI-23-0218
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Racial and ethnic disparities in guideline-recommended breast cancer treatment are well documented, however studies including diagnostic and staging procedures necessary to determine treatment indications are lacking. The purpose of this study was to characterize patterns in delivery of evidence-based services for the diagnosis, clinical workup, and first-line treatment of breast cancer by race-ethnicity.Methods: SEER-Medicare data were used to identify women diagnosed with invasive breast cancer between 2000 and 2017 at age 66 or older (n = 2,15,605). Evidence-based services included diagnostic procedures (diagnostic mammography and breast biopsy), clinical workup (stage and grade determination, lymph node biopsy, and HR and HER2 status determination), and treatment initiation (surgery, radiation, chemotherapy, hormone therapy, and HER2-targeted therapy). Poisson regression was used to estimate rate ratios (RR) and 95% confidence intervals (CI) for each service.Results: Black and American Indian/Alaska Native (AIAN) women had significantly lower rates of evidence-based care across the continuum from diagnostics through first-line treatment compared to non-Hispanic White (NHW) women. AIAN women had the lowest rates of HER2-targeted therapy and hormone therapy initiation. While Black women also had lower initiation of HER2-targeted therapy than NHW, differences in hormone therapy were not observed.Conclusions: Our findings suggest patterns along the continuum of care from diagnostic procedures to treatment initiation may differ across race-ethnicity groups.Impact: Efforts to improve delivery of guideline-concordant treatment and mitigate racial-ethnic disparities in healthcare and survival should include procedures performed as part of the diagnosis, clinical workup, and staging processes.
引用
收藏
页码:1312 / 1322
页数:11
相关论文
共 36 条
  • [21] Dual HER2 blockade in the first-line treatment of metastatic breast cancer - A retrospective population-based observational study in Danish patients
    Christensen, Thomas
    Berg, Tobias
    Nielsen, Lise Birk
    Andersson, Michael
    Jensen, Maj-Britt
    Knoop, Ann
    [J]. BREAST, 2020, 51 : 34 - 39
  • [22] First-line treatment patterns and outcomes in advanced non-small cell lung cancer in Sweden: a population-based real-world study with focus on immunotherapy
    Wagenius, Gunnar
    Vikstrom, Anders
    Berglund, Anders
    Salomonsson, Stina
    Bencina, Goran
    Hu, Xiaohan
    Chirovsky, Diana
    Brunnstrom, Hans
    [J]. ACTA ONCOLOGICA, 2024, 63 : 198 - 205
  • [23] Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study
    Lambertini, Matteo
    Ferreira, Arlindo R.
    Poggio, Francesca
    Puglisi, Fabio
    Bernardo, Antonio
    Montemurro, Filippo
    Poletto, Elena
    Pozzi, Emma
    Rossi, Valentina
    Risi, Emanuela
    Lai, Antonella
    Zanardi, Elisa
    Sini, Valentina
    Ziliani, Serena
    Minuti, Gabriele
    Mura, Silvia
    Grasso, Donatella
    Fontana, Andrea
    Del Mastro, Lucia
    [J]. ONCOLOGIST, 2015, 20 (08): : 880 - 889
  • [24] Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study
    Lambertini, Matteo
    Ferreira, Arlindo R.
    Di Meglio, Antonio
    Poggio, Francesca
    Puglisi, Fabio
    Sottotetti, Federico
    Montemurro, Filippo
    Poletto, Elena
    Bernardo, Antonio
    Risi, Emanuela
    Dellepiane, Chiara
    Sini, Valentina
    Minuti, Gabriele
    Grasso, Donatella
    Fancelli, Sara
    Del Mastro, Lucia
    [J]. CLINICAL BREAST CANCER, 2017, 17 (08) : 601 - +
  • [25] Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: A phase II study conducted by the Hellenic Cooperative Oncology Group
    Nicolaides, C
    Dimopoulos, MA
    Samantas, E
    Bafaloukos, D
    Kalofonos, C
    Fountzilas, G
    Razi, E
    Kosmidis, P
    Pavlidis, N
    [J]. ANNALS OF ONCOLOGY, 2000, 11 (07) : 873 - 875
  • [26] REAL-WORLD FIRST-LINE TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN TAIWAN: A POPULATION-BASED RETROSPECTIVE STUDY
    Hsia, Te-Chun
    Chung, Ching-Hu
    [J]. RESPIROLOGY, 2018, 23 : 297 - 298
  • [27] Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With First-line Therapies for Medicare Patients 65 Years and Older With Advanced Non-small-cell Lung Cancer: A Retrospective Study
    Bittoni, Marisa A.
    Arunachalam, Ashwini
    Li, Haojie
    Camacho, Ramon
    He, Jinghua
    Hong, Yichen
    Lubiniecki, Gregory M.
    Carbone, David P.
    [J]. CLINICAL LUNG CANCER, 2018, 19 (05) : E629 - E645
  • [28] Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy
    M Campone
    H Cortes-Funes
    D Vorobiof
    M Martin
    C F Slabber
    E Ciruelos
    E Bourbouloux
    C Mendiola
    F M Delgado
    C Colin
    V Aslanis
    P Fumoleau
    [J]. British Journal of Cancer, 2006, 95 : 1161 - 1166
  • [29] Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy
    Campone, M.
    Cortes-Funes, H.
    Vorobiof, D.
    Martin, M.
    Slabber, C. F.
    Ciruelos, E.
    Bourbouloux, E.
    Mendiola, C.
    Delgado, F. M.
    Colin, C.
    Aslanis, V.
    Fumoleau, P.
    [J]. BRITISH JOURNAL OF CANCER, 2006, 95 (09) : 1161 - 1166
  • [30] MO19391: An open-label safety study of bevacizumab plus taxane-based therapy as first-line treatment of patients with locally recurrent (LR) or metastatic breast cancer (MBC)
    Pierga, J.
    Pritchard, K. I.
    Cortes-Funes, H.
    Biganzoli, L.
    Thomssen, C.
    Franke, F. A.
    Smith, I. E.
    Bogdanova, N.
    Stroyakovskiy, D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)